Cynata Therapeutics Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
CYP
- Investments
-
4
Cynata Therapeutics General Information
Description
Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company pioneering a revolutionary approach to cell therapy with its proprietary Cymerus platform technology. The company operates in one business segment, namely the development and commercialisation of therapeutic products.
Contact Information
Website
www.cynata.comCorporate Office
- Level 3, 100 Cubitt Street
- Cremorne, Victoria 3121
- Australia
Corporate Office
- Level 3, 100 Cubitt Street
- Cremorne, Victoria 3121
- Australia
Cynata Therapeutics Timeline
Cynata Therapeutics Stock Performance
As of 13-Nov-2026, Cynata Therapeutics’s current market cap is $2.98M with 337M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.98M | 337M | 880K |
Cynata Therapeutics Financials Summary
As of 30-Sep-2026, Cynata Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 1,244 | 564 | 15,275 | 27,814 |
| EBITDA | (6,143) | (6,040) | (6,476) | |
| Net Income | (6,265) | (6,076) | (6,386) | |
| Total Assets | 932 | 4,702 | 5,607 | |
| Total Debt | 0 | 0 | 0 |
Cynata Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cynata Therapeutics Comparisons
Industry
Financing
Details
Cynata Therapeutics Competitors (4)
One of Cynata Therapeutics’s 4 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Syntara | Formerly VC-backed | Frenchs Forest, Australia | ||||
| Pluri | Corporation | Haifa, Israel | ||||
| Athersys | Formerly VC-backed | Cleveland, OH |
Cynata Therapeutics Patents
Cynata Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019900659-A0 | Method | Inactive | 28-Feb-2019 | ||
| AU-2020227617-A1 | Method for improving angiogenic potential of a mesenchymal stem cell | Inactive | 28-Feb-2019 | ||
| CA-3131395-A1 | Method for improving angiogenic potential of a mesenchymal stem cell | Pending | 28-Feb-2019 | ||
| EP-3931308-A1 | Method for improving angiogenic potential of a mesenchymal stem cell | Inactive | 28-Feb-2019 | ||
| EP-3931308-A4 | Method for improving angiogenic potential of a mesenchymal stem cell | Inactive | 28-Feb-2019 | C12N5/0691 |
Cynata Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cynata Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cynata Therapeutics Investments & Acquisitions (4)
Cynata Therapeutics’s most recent deal was a Corporate Asset Purchase with TekCyte (Wound Dressing Technology in Mawson Lakes, Australia) for . The deal was made on 01-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TekCyte (Wound Dressing Technology in Mawson Lakes, Australia) | 01-Jul-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Cynata | 01-Dec-2013 | Merger/Acquisition | Drug Discovery | ||
| Eco Quest | 25-Oct-2013 | Merger/Acquisition | Biotechnology | ||
| Cynata | 17-Sep-2012 | Corporate | Drug Discovery |
Cynata Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Cynata Therapeutics FAQs
-
When was Cynata Therapeutics founded?
Cynata Therapeutics was founded in 2003.
-
Where is Cynata Therapeutics headquartered?
Cynata Therapeutics is headquartered in Cremorne, Australia.
-
What is the size of Cynata Therapeutics?
Cynata Therapeutics has 2 total employees.
-
What industry is Cynata Therapeutics in?
Cynata Therapeutics’s primary industry is Drug Discovery.
-
Is Cynata Therapeutics a private or public company?
Cynata Therapeutics is a Public company.
-
What is Cynata Therapeutics’s stock symbol?
The ticker symbol for Cynata Therapeutics is CYP.
-
What is the current market cap of Cynata Therapeutics?
The current market capitalization of Cynata Therapeutics is $2.98M.
-
Who are Cynata Therapeutics’s competitors?
Mesoblast, Syntara, Pluri, and Athersys are competitors of Cynata Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
